期刊文献+

成骨不全家系分析 被引量:3

The study of clinical manifestations of osteogenesis imperfecta in a Chinese family.
原文传递
导出
摘要 目的探讨成骨不全(O I)家系遗传方式。方法对发现的O I家系进行现场调查,收集临床资料,绘制家系图谱;总结并分析临床特点。对3例患者采用双膦酸盐治疗,观察疗效。结果(1)临床特征:该家系共4代60人,临床诊断Ⅰ型O I的患者共20例,现场调查存在蓝巩膜15例;牙质形成不全者16例;进行性听力下降5例;发生骨折者3例;先证者母亲和表姐分别合并甲状腺乳头状癌和Turner综合征。(2)家系图谱显示遗传方式属于常染色体显性遗传。(3)治疗:先证者及其母亲和表姐接受双膦酸盐治疗2年,骨痛症状明显改善,骨密度显著增加,治疗期间未发生新的骨折。结论(1)该中国汉族O I家系临床诊断符合Ⅰ型O I,遗传方式为常染色体显性遗传。(2)双膦酸盐可能是治疗O I的有效药物。 Objective To study the clinical characters, the mode of inheritance of osteogenesis Imperfecta in a Chinese Family and effect of bisphosphonate on Osteogenesis Imperfecta. Methods Clinical data of proband and their family members were collected. The family patterns were mapped, clinical features were summarized and analyzed. Results ( 1 ) Clinical features :There are sixty members of four generations in the family. 20 cases including proband's mother and cousin were diagnosed as having OI type Ⅰ based on clinical manifestations. 15 cases of blue sclera, 16 cases of dentinogenesis imperfecta, 5 cases of hearing loss and 3 cases of fracture. Thyroid cancer and Turner's syndrome was found in Proband's mother and cousin respectively. (2)The genetic map showed that the disease was autosomal dominant inheritance. (3)Treatment :The proband, her mother and her cousin were treated with alendronate for two years. Bone pain relieved and bone mineral density increased significantly, and no fracture occurred so far. Conclusion ( 1 ) This OI family was diagnosed as having OI type Ⅰ. The mode of inheritance is autosomal dominant inheritance. ( 2 ) Bisphosphonates may be an effective drug for treatment of OI.
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2009年第3期228-230,共3页 Chinese Journal of Practical Internal Medicine
基金 北京市自然科学基金资助项目(7072073) 解放军总医院苗圃基金(06MP01)
关键词 成骨不全 Ⅰ型胶原 家系 双膦酸盐 osteogenesis imperfecta type Ⅰ collagen family bisphosphonate
  • 相关文献

参考文献10

  • 1Marini JC, Forlino A, Cabral WA, et al. Consortium for osteogenesis imperfecta mutations in the helical domain of type Ⅰ collagen : regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans[ J]. Hum Mutat,2007,28:209-221.
  • 2Byers PH,Cole WG. Osteogenesis imperfecta[ M]. New York :Willey-liss,2002:385 - 430.
  • 3Kuurila K,Kaitila l,Johansson R,et al. Hearing loss in Finnish adults with osteogenesis imperfecta: a nationwide survey [J]. Ann Otol Rhinol Laryngol,2002, 111:939 - 946.
  • 4瘳二无,超楚生,伍汉文,等.内分泌学[M].北京:人民卫生出版社,2004:1869-1874.
  • 5Cepollaro C, Gonnelli S, Pondrelli C, et al. Osteogenesis imperfeeta bone turnover,bone density,and uhersound parameters[J]. Calcif Tissue Int, 1999,65 : 129 - 132.
  • 6Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfectal[ J]. J Med Genet, 1979,16 : 101 - 116.
  • 7Glorieux FH ,Rauch F, Plorkin H ,et al. Type V Osteogenesis imperfecta:a new form of brittle bone disease[J]. J Bone Miner Res, 2000,15 : 1650 - 1658.
  • 8Glofieux FH, Ward LM, Rauch F, et al. Osteogenesis imperfecta type Ⅵ:a form of brittle bone disease with a mineralization defect [J]. J Bone Minter Res,2002,17:30 - 38.
  • 9Ward LM,Ranch F,Travers R, et al. Osteogenesis imperfecta type Ⅶ:an autosomal recessive form of brittle bone disease[ J]. Bone, 2002,31:12 - 18.
  • 10Rauch F, Glorieux FH. Osteogenesis imperfecta [ J ]. Lancet. 2004 363 : 1377 - 1385.

同被引文献16

  • 1王社芬,王春英.人体语言在课堂教学中的应用[J].中华护理杂志,1994,29(3):168-170. 被引量:11
  • 2Marini J C, Forlino A, Cabral W A, et al. Consortium for osteogenesis imperfeeta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans [J]. Hum Mutat, 2007, 28(3) : 209 -221.
  • 3Byers P H, Cole W G . Osteogenesis imperfecta [ M ]// Royce P M, Steinmann B, eds. Connective Tissue and Its Heritable Disorders. 2nd ed. New York: Wileyliss, 2002:385 -430.
  • 4Sillence D O, Senn A, Danks D M. Genetic heterogeneity in osteogenesis imperfecta [J]. J Med Genet, 1979, 16(2) : 101 -116.
  • 5Marini J C, Forlmo A, Cabral-W A, et al. Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and pmteoglyeans[J]. Hum Murat, 2007, 28 (3) : 209 - 221.
  • 6St(o)ss H. Pathologic anatomy of osteogenesis imperfecta.Light and electron microscopic studies of supportive tissue and skin[J].Veroffentlichungen aus der Pathologie,1990.1-88.
  • 7Devogelaer JP,Malghem J,Maldague B. Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta[J].Skeletal Radiology,1987.360-363.
  • 8Ward LM,Rauch F,Whyte MP. Alendronate for the treatment of pediatric osteogenesis imperfecta:a randomized placebo-controlled study[J].Journal of Clinical Endocrinology and Metabolism,2011.355-364.
  • 9Rauch F,Glorieux FH. Bisphosphonate treatment in osteogenesis imperfecta:which drug,for whom,for how long[J].Annals of Medicine,2005.295-302.
  • 10Rauch F,Plotkin H,Zeitlin L. Bonemass,size,and density in children and adolescent swith osteogenesis imperfecta:effect of intravenous pamidronate therapy[J].Journal of Bone and Mineral Research,2003.610-614.

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部